Literature DB >> 17005652

Modulation of DNA vaccine-elicited CD8+ T-lymphocyte epitope immunodominance hierarchies.

Jinyan Liu1, Bonnie A Ewald, Diana M Lynch, Anjali Nanda, Shawn M Sumida, Dan H Barouch.   

Abstract

Generating broad cellular immune responses against a diversity of viral epitopes is a major goal of current vaccine strategies for human immunodeficiency virus type 1 (HIV-1) and other pathogens. Virus-specific CD8(+) T-lymphocyte responses, however, are often highly focused on a very limited number of immunodominant epitopes. For an HIV-1 vaccine, the breadth of CD8(+) T-lymphocyte responses may prove to be critical as a result of the need to cover a wide diversity of viral isolates in the population and to limit viral escape from dominant epitope-specific T lymphocytes. Here we show that epitope modification strategies can alter CD8(+) T-lymphocyte epitope immunodominance hierarchies elicited by a DNA vaccine in mice. Mice immunized with a DNA vaccine expressing simian immunodeficiency virus Gag lacking the dominant D(b)-restricted AL11 epitope generated a marked and durable augmentation of responses specific for the subdominant D(b)-restricted KV9 epitope. Moreover, anatomic separation strategies and heterologous prime-boost regimens generated codominant responses against both epitopes. These data demonstrate that dominant epitopes can dramatically suppress the immunogenicity of subdominant epitopes in the context of gene-based vaccines and that epitope modification strategies can be utilized to enhance responses to subdominant epitopes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17005652      PMCID: PMC1676306          DOI: 10.1128/JVI.01348-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  25 in total

1.  Sequences that flank subdominant and cryptic epitopes influence the proteolytic generation of MHC class I-presented peptides.

Authors:  A X Mo; S F van Lelyveld; A Craiu; K L Rock
Journal:  J Immunol       Date:  2000-04-15       Impact factor: 5.422

Review 2.  Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses.

Authors:  J W Yewdell; J R Bennink
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

3.  Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes.

Authors:  Nicole Frahm; Photini Kiepiela; Sharon Adams; Caitlyn H Linde; Hannah S Hewitt; Kaori Sango; Margaret E Feeney; Marylyn M Addo; Mathias Lichterfeld; Matthew P Lahaie; Eunice Pae; Alysse G Wurcel; Timothy Roach; M Anne St John; Marcus Altfeld; Francesco M Marincola; Corey Moore; Simon Mallal; Mary Carrington; David Heckerman; Todd M Allen; James I Mullins; Bette T Korber; Philip J R Goulder; Bruce D Walker; Christian Brander
Journal:  Nat Immunol       Date:  2005-12-20       Impact factor: 25.606

4.  Immunodomination in the evolution of dominant epitope-specific CD8+ T lymphocyte responses in simian immunodeficiency virus-infected rhesus monkeys.

Authors:  Michael H Newberg; Kimberly J McEvers; Darci A Gorgone; Michelle A Lifton; Susanne H C Baumeister; Ronald S Veazey; Jörn E Schmitz; Norman L Letvin
Journal:  J Immunol       Date:  2006-01-01       Impact factor: 5.422

5.  Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys.

Authors:  Anjali Nanda; Diana M Lynch; Jaap Goudsmit; Angelique A C Lemckert; Bonnie A Ewald; Shawn M Sumida; Diana M Truitt; Peter Abbink; Michael G Kishko; Darci A Gorgone; Michelle A Lifton; Ling Shen; Angela Carville; Keith G Mansfield; Menzo J E Havenga; Dan H Barouch
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

6.  Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys.

Authors:  D H Barouch; A Craiu; S Santra; M A Egan; J E Schmitz; M J Kuroda; T M Fu; J H Nam; L S Wyatt; M A Lifton; G R Krivulka; C E Nickerson; C I Lord; B Moss; M G Lewis; V M Hirsch; J W Shiver; N L Letvin
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

7.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Authors:  John W Shiver; Tong-Ming Fu; Ling Chen; Danilo R Casimiro; Mary-Ellen Davies; Robert K Evans; Zhi-Qiang Zhang; Adam J Simon; Wendy L Trigona; Sheri A Dubey; Lingyi Huang; Virginia A Harris; Romnie S Long; Xiaoping Liang; Larry Handt; William A Schleif; Lan Zhu; Daniel C Freed; Natasha V Persaud; Liming Guan; Kara S Punt; Aimin Tang; Minchun Chen; Keith A Wilson; Kelly B Collins; Gwendolyn J Heidecker; V Rose Fernandez; Helen C Perry; Joseph G Joyce; Karen M Grimm; James C Cook; Paul M Keller; Denise S Kresock; Henryk Mach; Robert D Troutman; Lynne A Isopi; Donna M Williams; Zheng Xu; Kathryn E Bohannon; David B Volkin; David C Montefiori; Ayako Miura; Georgia R Krivulka; Michelle A Lifton; Marcelo J Kuroda; Jörn E Schmitz; Norman L Letvin; Michael J Caulfield; Andrew J Bett; Rima Youil; David C Kaslow; Emilio A Emini
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

8.  Development of a preventive vaccine for Ebola virus infection in primates.

Authors:  N J Sullivan; A Sanchez; P E Rollin; Z Y Yang; G J Nabel
Journal:  Nature       Date:  2000-11-30       Impact factor: 49.962

9.  Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines.

Authors:  Shawn M Sumida; Paul F McKay; Diana M Truitt; Michael G Kishko; Janelle C Arthur; Michael S Seaman; Shawn S Jackson; Darci A Gorgone; Michelle A Lifton; Norman L Letvin; Dan H Barouch
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

10.  Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia.

Authors:  T M Allen; D H O'Connor; P Jing; J L Dzuris; B R Mothé; T U Vogel; E Dunphy; M E Liebl; C Emerson; N Wilson; K J Kunstman; X Wang; D B Allison; A L Hughes; R C Desrosiers; J D Altman; S M Wolinsky; A Sette; D I Watkins
Journal:  Nature       Date:  2000-09-21       Impact factor: 49.962

View more
  39 in total

1.  Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions.

Authors:  Ritu R Bradley; Lori F Maxfield; Diana M Lynch; Mark J Iampietro; Erica N Borducchi; Dan H Barouch
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection.

Authors:  Ritu R Bradley; Diana M Lynch; Mark J Iampietro; Erica N Borducchi; Dan H Barouch
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

3.  Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors.

Authors:  Elizabeth G Rhee; Joseph N Blattman; Sudhir P Kasturi; R Phelps Kelley; David R Kaufman; Diana M Lynch; Annalena La Porte; Nathaniel L Simmons; Sarah L Clark; Bali Pulendran; Philip D Greenberg; Dan H Barouch
Journal:  J Virol       Date:  2010-10-20       Impact factor: 5.103

4.  Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation.

Authors:  Jinyan Liu; Rune Kjeken; Iacob Mathiesen; Dan H Barouch
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

5.  Memory CD8+ T cells specific for a single immunodominant or subdominant determinant induced by peptide-dendritic cell immunization protect from an acute lethal viral disease.

Authors:  Sanda Remakus; Daniel Rubio; Xueying Ma; Alessandro Sette; Luis J Sigal
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

6.  Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling.

Authors:  Kylie M Quinn; Daniel E Zak; Andreia Costa; Ayako Yamamoto; Kathrin Kastenmuller; Brenna J Hill; Geoffrey M Lynn; Patricia A Darrah; Ross W B Lindsay; Lingshu Wang; Cheng Cheng; Alfredo Nicosia; Antonella Folgori; Stefano Colloca; Riccardo Cortese; Emma Gostick; David A Price; Jason G D Gall; Mario Roederer; Alan Aderem; Robert A Seder
Journal:  J Clin Invest       Date:  2015-02-02       Impact factor: 14.808

7.  Engineering recombinant reoviruses with tandem repeats and a tetravirus 2A-like element for exogenous polypeptide expression.

Authors:  Aleksander A Demidenko; Joseph N Blattman; Negin N Blattman; Philip D Greenberg; Max L Nibert
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-29       Impact factor: 11.205

8.  Longitudinal requirement for CD4+ T cell help for adenovirus vector-elicited CD8+ T cell responses.

Authors:  Nicholas M Provine; Rafael A Larocca; Pablo Penaloza-MacMaster; Erica N Borducchi; Anna McNally; Lily R Parenteau; David R Kaufman; Dan H Barouch
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

Review 9.  HIV-1 vaccine development after STEP.

Authors:  Dan H Barouch; Bette Korber
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

10.  Controlling influenza by cytotoxic T-cells: calling for help from destroyers.

Authors:  Michael Schotsaert; Lorena Itatí Ibañez; Walter Fiers; Xavier Saelens
Journal:  J Biomed Biotechnol       Date:  2010-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.